Search General Info
Search Education
Search Partnering Companies
![BIO International Convention](/sites/default/files/2021-09/_BIO_CONV_Logo-White.png)
FivepHusion is an advanced clinical stage biotech company developing Deflexifol™, a novel enhanced drug formulation designed to address the safety and efficacy limitations of standard of care chemotherapy for the treatment of solid tumors with significant unmet medical need.
Deflexifol™ combines the chemotherapeutic drug 5-fluorouracil (5-FU) and its biomodulator leucovorin, which improves the anti-tumor activity of 5-FU. These drugs are commonly used globally to treat various solid tumors including colorectal, pancreatic and gastric cancers. The Deflexifol™ all-in-one formulation delivers both agents simultaneously at a physiological pH, thereby improving their safety, tolerability, and anti-tumor activity.
FivepHusion’s strategy is to develop Deflexifol™ via the 505(b)(2) pathway as the new Gold Standard of Care™ for solid tumor treatment, with a planned global phase III pivotal trial in 1st line mCRC to commence in 2024.
Deflexifol™ combines the chemotherapeutic drug 5-fluorouracil (5-FU) and its biomodulator leucovorin, which improves the anti-tumor activity of 5-FU. These drugs are commonly used globally to treat various solid tumors including colorectal, pancreatic and gastric cancers. The Deflexifol™ all-in-one formulation delivers both agents simultaneously at a physiological pH, thereby improving their safety, tolerability, and anti-tumor activity.
FivepHusion’s strategy is to develop Deflexifol™ via the 505(b)(2) pathway as the new Gold Standard of Care™ for solid tumor treatment, with a planned global phase III pivotal trial in 1st line mCRC to commence in 2024.
![](https://www.abstractscorecard.com/uploads/Tasks/upload/20525/EOISBJNL-1545458-1-JPG.jpg)
Ticker:
Not Provided
Exchange:
Not Provided
Company Type:
Not Provided
Company Website:
Company HQ State:
New South Wales
Company HQ Country:
Australia
Year Founded:
2018
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Deflexifol™, a novel advanced clinical-stage drug reformulation that enhances chemotherapy for a range of adult and childhood cancers with significant unmet medical need.
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Deflexifol™
Speaker
![](https://www.conferenceharvester.com/uploads/harvester/photos/EOISBJNL-Presenter-ToouliC.jpg)
BIO DOUBLE HELIX SPONSORS
![Sanofi logo](/sites/default/files/2022-05/Sanofi_Color_jpg_Double%20Helix.jpg)
![Eli Lilly and Company](/sites/default/files/2019-09/Eli%20Lilly%20and%20Company.png)
![Amgen logo](/sites/default/files/2022-05/Amgen_Color_png_Double%20Helix.png)
![Genentech logo](/sites/default/files/2022-05/Genentech_Color_png_Double%20Helix.png)
![Merck_logo_2022](/sites/default/files/2022-10/Merck_Color_.png)
![Avantor](/sites/default/files/2021-06/Avantor-BIO-DH-578.png)
![GSK logo](/sites/default/files/2023-04/gsk_color_png.png)
BIO HELIX SPONSORS
![Johnson and Johnson](/sites/default/files/2021-06/Johnson-Johnson-BIO-DH-578.png)
![Takeda logo](/sites/default/files/2022-05/Takeda_Color_jpg_Premier.jpg)
![Travere logo](/sites/default/files/2022-05/Travere_Color_png_Helix%20large.png)
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2024 All Rights Reserved